Clinical trial IMMU-132-09
Phase 3 Study of Sacituzumab Govitecan-hziy (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Immunomedics |
| EudraCT Identifier | 2018-004201-33 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03901339 |
| Inclusion criteria | HR+/HER2- |
| Last update |